News

Roche reported an operating profit of CHF15.012bn for the FY 2009, compared to CHF13.896bn for the FY 2008, an increase of 14%. The net income of the company

Reportedly, in the trial, VX-809 showed a decline in sweat chloride at both the 100mg and 200mg once-daily doses, suggesting that the activity of the CFTR protein was

The compound was originally developed by Kissei Pharmaceutical in Japan and was obtained under license by Recordati for the whole of Europe and 18 countries in the Middle

The Helicos Genetic Analysis System is the molecule sequencing technology that enables scientists to conduct revolutionary studies to understand genome biology and regulation. Genetic analysis with Helicos’ technology

In the study, 200 healthy human volunteers took a once daily dose of oral interferon or placebo for 16 weeks during the Australian cold and flu season. There

The NuroPro AD test was developed to help clinicians distinguish patients with Alzheimer’s disease from normal individuals and patients with other neurological disorders. The test, developed by Power3,

The company said that the complaint alleges that certain processes and methods performed by XenoTech associated with its in-vitro drug testing services and its pooled cryopreserved hepatocyte products,

The primary efficacy endpoint for Hokusai VTE is the recurrence of symptomatic VTE. The primary safety assessment of the trial is the incidence of major and clinically relevant

Dr Kobayashi will focus on expanding UBC’s operations in Japan with specific oversight on its line of services aimed at improving the reliability of clinical study results. Dr